Minneapolis, Minnesota-based Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, ...

Bio-Techne Corp. closed 27.94% short of its 52-week high of $72.16, which the company achieved on January 22nd.

Bio-Techne develops specialized reagents and diagnostic solutions for global research and clinical markets in the life ...

What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones ...

RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...

Bio-Techne Corporation TECH is set to release second-quarter fiscal 2026 results on Feb. 4, before the opening bell. The life science and diagnostic product maker posted adjusted earnings per share ...

Bio-Techne (NASDAQ:TECH) is preparing to release its quarterly earnings on Wednesday, 2026-02-04. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court ...

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

Bio-Techne Corporation TECH recently announced new advancements in its spatial biology portfolio for the RNAscope ISH technology and the Lunaphore COMET. Research highlights the potential role of ...